On 29 May 2019, orphan designation (EU/3/19/2161) was granted by the European Commission to Worphmed World Orphan Medicines Limited, United Kingdom, for diacerein for the treatment of epidermolysis bullosa.
The sponsorship was transferred to Worphmed World Orphan Medicines Limited, Italy, in August 2019.
Treatment of epidermolysis bullosa
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: